Partenaires
OPi
OPi, Pharmaceuticals for Rare Diseases is a biopharmaceutical company engaged in the development and marketing of innovative drugs to treat rare and severe diseases. OPi applies its skills and capabilities in research, pharmaceutical and clinical development, regulatory affairs, medical affairs and marketing to ultimately work for patients suffering from these diseases. OPi explores new therapeutic approaches and also works as a "re-discovery engine", turning unnoticed drug opportunities into products that are made available to the hospitals physicians and pharmacists, to help them meeting the medical needs of the patients and their families, and improving their quality of life.

Dedicated to help people with rare and severe diseases, the company is focused on the areas of haematological cancers, while being also active in neurology and toxicology. OPi is also active in other therapeutic areas, with commercialised hospital products targeting unmet medical needs in neurology, metabolic diseases and clinical toxicology. Headquartered in Lyon, France, OPi has been built by identifying, developing or acquiring and marketing hospital products for serious diseases.
Discover www.orphan-opi.com
07/10/2010
Save the date : 4th edition of Lyonbiopole Partnering Days![]()
16/03/2010
Registrations are open : next edition of FABS (French American Biotechnology Symposium)![]()
04/03/2010
Lyonbiopole co-organizes with Minalogic a lunch topic on « how to fund your international development! »![]()
01/03/2010
Lyonbiopole is delighted to greet Professor Leroy Hood in Lyon![]()












